2Segment information

PolyPeptide generates revenue that is presented in Note 3. Effective as of the start of the current reporting period, for a more concise discussion of business drivers, the Company now has two primary business areas “Commercial revenue” and “Development revenue”.
This revised presentation reflects the distinction between revenue from ongoing commercial supply activities and revenue from early-stage development collaborations.

The chief operating decision maker (i.e., the Executive Committee) reviews revenue generated within each business area but does not review results at this disaggregated level. As a result, the two business areas are not considered two separate operating segments since only revenue information for each area is reviewed by the chief operating decision maker. The Group continues to have one operating segment in accordance with IFRS 8 – Operating segments.

The segment disclosures are thus provided in accordance with the requirements applicable for entities that have a single reportable segment.

Revenue from major customers (10% or more of total revenue)

In 2025, revenues of approximately kEUR 56,890 and kEUR 47,980, respectively, were derived from two customers.
In 2024, revenues of approximately kEUR 43,900 and kEUR 41,200, respectively, were derived from two customers.

Geographical areas

Shown below are the carrying amounts of non-current assets other than deferred income tax assets and other financial assets, broken down by location of the assets. Related additions to intangible assets and property, plant and equipment (PP&E) during the year and revenues generated from the location of the assets are shown as well.